BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25202077)

  • 1. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
    Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
    Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
    Goto T; Shinmura K; Yokomizo K; Sakuraba K; Kitamura Y; Shirahata A; Saito M; Kigawa G; Nemoto H; Sanada Y; Hibi K
    Anticancer Res; 2012 May; 32(5):1757-62. PubMed ID: 22593457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
    Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
    Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.
    Negri FV; Azzoni C; Bottarelli L; Campanini N; Mandolesi A; Wotherspoon A; Cunningham D; Scartozzi M; Cascinu S; Tinelli C; Silini EM; Ardizzoni A
    Anticancer Res; 2013 Oct; 33(10):4611-7. PubMed ID: 24123038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
    Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups: a retrospective analysis of biomarkers in matched primary tumor and lymph node metastases.
    Karamitopoulou E; Zlobec I; Koumarianou A; Patsouris ES; Peros G; Lugli A
    Cancer; 2010 Oct; 116(19):4474-86. PubMed ID: 20572035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
    Ren DN; Kim IY; Koh SB; Chang SJ; Eom M; Yi SY; Seong SH; Kim MD; Bronner MP; Cho MY
    J Surg Oncol; 2009 Dec; 100(7):546-52. PubMed ID: 19722231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
    Huh JW; Kim HR; Kim YJ
    J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
    Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
    Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas.
    Furlan D; Sahnane N; Carnevali I; Cerutti R; Bertoni F; Kwee I; Uccella S; Bertolini V; Chiaravalli AM; Capella C
    Hum Pathol; 2008 Oct; 39(10):1483-94. PubMed ID: 18619649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.